<DOC>
	<DOCNO>NCT00859937</DOCNO>
	<brief_summary>This phase II trial study well dasatinib work treat patient recurrent metastatic malignant salivary gland tumor . Dasatinib may stop growth tumor cell block enzymes need cell growth .</brief_summary>
	<brief_title>Dasatinib Treating Patients With Recurrent Metastatic Malignant Salivary Gland Tumors</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine objective response rate ( complete partial response ) patient recurrent metastatic c-KIT-expressing adenoid cystic carcinoma ( ACC ) salivary gland treat dasatinib . II . Determine progression-free survival patient . SECONDARY OBJECTIVES : I . Determine duration response patient non-ACC c-KIT-expressing ACC salivary gland . II . Determine stable disease rate duration stable disease patient . III . Determine median survival patient . IV . Determine overall survival patient . V. Determine safety tolerability dasatinib patient . VI . Determine progression-free survival patient non-ACC salivary gland . TERTIARY OBJECTIVES : I. Correlate biomarkers relate Src signal transduction clinical response dasatinib patient non-ACC c-KIT-expressing ACC salivary gland . II . Determine activate mutation PDGFA KIT associate response patient c-KIT-expressing ACC salivary gland . OUTLINE : This multicenter study . Patients assign 1 2 cohort accord histologic subtype ( adenoid cystic carcinoma [ ACC ] v non-ACC ) . Patients receive oral dasatinib twice daily day 1-28 . Courses repeat every 28 day absence disease progression unacceptable toxicity . Blood tumor tissue sample collect baseline correlative laboratory biomarker pharmacogenomic study . Samples analyze total c-Src phosphorylated Src expression IHC ; polymorphism gene rearrangements/activating mutation PDGFA ( within exon 18 12 ) KIT ( within exon 9 , 11 , 13 , 27 ) PCR ; additional biomarkers associate Src signal transduction and/or dasatinib response ( e.g. , phospho-KIT , phospho-PDGFR , EPHA2 , VEGF , Stat3 , Bcl-x , survivin , cyclin D1 , p27_Kip ) IHC . After completion study therapy , patient follow 4 week .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Salivary Gland Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Adenoid Cystic</mesh_term>
	<mesh_term>Carcinoma , Mucoepidermoid</mesh_term>
	<mesh_term>Carcinoma , Acinar Cell</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>Histologically cytologically confirm malignant salivary gland tumor , include one follow histologic subtypes : Adenoid cystic carcinoma ( ACC ) cKIT overexpression , define CD 117 stain IHC 25 % tumor cell NonACC cKIT overexpression require Not amenable potentially curative surgery radiotherapy Evidence disease progression ( i.e. , objective growth exist tumor ) within past 4 month Radiographically measurable disease , define ≥ 1 lesion accurately measure ≥ 1 dimension ≥ 20 mm conventional technique ≥ 10 mm spiral CT scan No active pleural pericardial effusion grade No know brain metastasis , unless patient meet follow criterion : Neurologic status stable ≥ 8 week completion definitive local therapy ( surgery radiotherapy ) No neurologic dysfunction would confound study result ECOG performance status ( PS ) 02 OR Karnofsky PS 60100 % Life expectancy &gt; 12 week WBC count ≥ 3,000/mm^3 ANC ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hemoglobin ≥ 9 g/dL Serum calcium ≤ 12.0 mg/dL Total serum bilirubin normal AST/ALT ≤ 2.5 time upper limit normal Creatinine normal OR creatinine clearance ≥ 60 mL/min Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No QTc prolongation ( define QTc interval ≥ 500 msec ) , serious ventricular arrhythmia ( ventricular fibrillation ventricular tachycardia ≥ 3 beat row ) , significant ECG abnormality None follow condition : Serious nonhealing wound , ulcer , bone fracture Abdominal fistula , gastrointestinal ( GI ) perforation , intraabdominal abscess within past 28 day Cerebrovascular accident transient ischemic attack within past 12 month Myocardial infraction , cardiac arrhythmia , stable/unstable angina , symptomatic congestive heart failure , coronary/peripheral artery bypass graft stenting within past 6 month Pulmonary embolism within past 12 month Ejection fraction &lt; normal echocardiograph ( required patient know history congestive heart failure , low ejection fraction , clinical symptoms/findings consistent congestive heart failure ) No condition would impair ability swallow retain dasatinib tablet ( e.g. , GI tract disease result inability take oral medication , requirement IV alimentation , active peptic ulcer disease ) No concurrent uncontrolled illness include , limited , follow : Ongoing active infection Psychiatric illness social situation would limit compliance study requirement No history allergic reaction attribute compound similar chemical biologic composition dasatinib No diagnosis second malignancy within past 5 year except fully treat basal cell carcinoma , squamous cell skin cancer , stage I carcinoma , adequately treat situ carcinoma evidence recurrent disease within past 12 month Recovered prior therapy No prior treatment target agent inhibit VEGFR , BCRABL , cSrc , cKIT , PDGFβ receptor , EPHA2 ( e.g. , imatinib mesylate ) No prior surgical procedure affect absorption More 4 week since prior chemotherapy ( 6 week nitrosoureas mitomycin C ) radiotherapy At least 4 week since prior major surgery More 7 day since prior concurrent agent proarrhythmic potential More 7 day since prior concurrent potent CYP3A4 inhibitor ( e.g. , ketoconazole , itraconazole , erythromycin , clarithromycin , ritonavir , atazanavir , indinavir , nelfinavir , saquinavir , telithromycin , voriconazole , nefazodone ) At least 5 halflives since prior concurrent medication may cause QTc prolongation No concurrent potent CYP3A4 inducer ( e.g. , dexamethasone , phenytoin , carbamazepine , rifampin , phenobarbital , St. John wort 's , aminoglutethimide , primidone , rifabutin , nevirapine , oxcarbazepine , rifapentine , fosphenytoin , pentobarbital ) No concurrent investigational agent No concurrent enzymeinducing anticonvulsant ( e.g. , carbamazepine , phenobarbital , phenytoin ) No concurrent combination antiretroviral therapy HIVpositive patient No concurrent grapefruit grapefruit juice No concurrent anticancer agent therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>